3-FA
3-fluoroamphetamine
Viewing r1 — May 7, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
3-FA (3-fluoroamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is a fluorinated structural analog of amphetamine, most closely related in character to prescription amphetamine. It releases dopamine and norepinephrine into the brain's synapses, producing the focused drive and wakefulness characteristic of amphetamine-type stimulants.[1][2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
amphetamine, methamphetamine, cocaine +1 moreamphetamine, methamphetamine, cocaine, other dopaminergic stimulants show less
3-FA was synthesized at the National Institute on Drug Abuse as part of a systematic research series exploring treatments for cocaine addiction.[1] Animal studies showed it could reduce cocaine self-administration, but no clinical trials followed.[3][4] It appeared on European research chemical markets around 2009 and remains available through unregulated vendors.[5]
Subjective effects include wakefulness, concentrated focus, motivation, appetite suppression, and physical stimulation. The experience is purely functional — clean drive without emotional warmth or euphoria, placing it closer to prescription amphetamine than to MDMA. Compulsive redosing, anxiety, and a pronounced crash of fatigue and low mood are characteristic unsought effects.
3-FA carries significant abuse liability — its abuse potential is comparable to methamphetamine[6] — and potent norepinephrine release places serious strain on the heart. Tolerance to the desired effects develops faster than tolerance to cardiac stress, so chasing the effect increases heart risk disproportionately. The evidence base is almost entirely preclinical — no human pharmacokinetic or clinical safety data exist.
History[edit]
Discovery
3-FA was synthesized as part of the PAL (Phenylethylamine/amphetamine Library) series at the National Institute on Drug Abuse, led by researchers Richard B. Rothman, Bruce E. Blough, and Michael H. Baumann. The library systematically mapped how substituent positions on the amphetamine scaffold control monoamine selectivity. PAL-353 was first pharmacologically characterized in 2005.[1]
Preclinical therapeutic research
The compound was studied as a candidate medication for cocaine use disorder. It reduced cocaine self-administration in primates,[3][4][7] substituted for cocaine in discrimination tests,[3] and showed promise for transdermal delivery as a route that could sustain blood levels while limiting abuse potential.[8][9] No clinical trials have been registered as of May 2026.
Research chemical market
3-FA appeared on European research chemical markets around January 2009, first notified to the European Early Warning System by Belgian authorities.[5] It followed 4-fluoroamphetamine onto the market and is typically sold as a white crystalline powder in hydrochloride salt form.
The PAL-353 designation reflects its origin as a numbered library entry rather than a substance designed for human use. Unlike 4-FA, which found a distinct recreational identity in Dutch nightlife culture, 3-FA occupies a quieter niche — valued for functional stimulation rather than recreation. Its utilitarian reputation is consistent with its pharmacology: dopamine without serotonin produces drive without warmth.
Chemistry[edit]
Structural class
3-FA is a ring-fluorinated structural analog of amphetamine, with a fluorine atom at the meta (3-) position of the phenyl ring. Three positional isomers exist — 2-FA, 3-FA, and 4-FA — and the position of fluorine determines each compound's dopamine-versus-serotonin selectivity. The meta position gives 3-FA the highest dopamine-over-serotonin selectivity in the series.[2] Its systematic name is 1-(3-fluorophenyl)propan-2-amine.
Molecular properties
| Molecular formula | C₉H₁₂FN |
| Molecular weight | 153.20 g/mol |
Stereochemistry
3-FA has a chirality center and is typically encountered as a racemic mixture of two mirror-image forms. Enantioseparation has been demonstrated analytically.[10] The free base is highly lipophilic — approximately 70% permeated through human skin in vitro[9] — indicating strong passive skin absorption.
Pharmacology[edit]
Mechanism of action
3-FA works by entering neurons through monoamine transporters and reversing their function, driving dopamine and norepinephrine into the synapse — the same mechanism as amphetamine.[1][2] It releases catecholamines at concentrations roughly 80–120 times lower than those needed to release serotonin, making it far more dopaminergic than serotonergic.[1][2] This selectivity is what separates its experience from entactogens like MDMA.
In vivo effects
Animal studies confirmed this profile: in rats, 3-FA produced the largest dopamine surge among tested fluorinated amphetamines[2][11] and fully substitutes for methamphetamine in drug discrimination tests in mice.[6] It also suppresses appetite at a rate comparable to amphetamine.[12]
Pharmacokinetics
No human pharmacokinetic data exist. In rats, the plasma half-life is approximately 2.3 hours after intravenous dosing.[8] Metabolism has not been studied in any species — by analogy with related fluoroamphetamines, beta-hydroxylation and ring hydroxylation followed by conjugation are expected.[13]inferred
Neuroscience[edit]
Where it acts
3-FA's main target is the brain's mesolimbic pathway — the projection from the midbrain to the nucleus accumbens that assigns motivational drive to actions. Rat studies show it elevates nucleus accumbens dopamine 5–14-fold above baseline, the highest elevation among tested fluorinated amphetamines.[2][11] This surge drives the wakefulness, goal-directed motivation, and reinforcing pull of the compound.
Why it matters
Dopamine drives wanting — the urgent push toward a goal — more than liking, which is about pleasure itself. 3-FA amplifies wanting strongly, explaining the compulsive redosing and task-locked focus characteristic of dopamine-selective stimulants. Repeated use adapts the brain against this effect, producing tolerance and a withdrawal state of low mood and fatigue.inferred
Whether 3-FA shares methamphetamine's capacity to damage dopamine nerve terminals through oxidative stress is entirely unknown — no neurotoxicity studies have been conducted despite comparable dopamine-releasing potency.safety citation needed
Subjective Effects[edit]
3-FA produces clean, functional stimulation — concentrated focus, heightened motivation, and sharpened task engagement without perceptual shifts or emotional warmth. The effect is characterized by drive rather than pleasure, making it more utilitarian than recreational.
In comparative terms, 3-FA sits closest to d-amphetamine and is notably more functional than its positional isomer 4-FA, which carries a hybrid stimulant-entactogen character from greater serotonin release. Where 4-FA brings warmth and sociability, 3-FA delivers pure, directed drive.
Effect Grid
Clear stimulant effects with pronounced wakefulness, cognitive euphoria, focus enhancement, and motivation enhancement. Thought acceleration is noticeable — mental processing feels faster and more directed. Appetite suppression becomes significant, often eliminating hunger awareness entirely during the peak period. This is the typical functional and recreational dose range.
Physical stimulation is evident: elevated heart rate, possible bruxism, and mild excessive sweating. Body high is present but secondary to cognitive effects. The experience is characterized more by driven motivation than by hedonic pleasure — consistent with 3-FA's dopamine-selective, non-entactogenic profile.
Peak effects last approximately 2–3 hours, with a total subjective duration of 4–6 hours. Insomnia is likely if taken within 6 hours of intended sleep.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Dry mouth · Insomnia · Pupil dilation · Restlessness · Physical fatigue · Muscle tension · Excessive sweating · Heart rate perception changes · Tingling / electric sensations · Dehydration sensation · Tactile euphoria · Bodily lightness · Body high · Constipation · Headache · Nausea · Sexual arousal enhancement · Trembling · Bruxism · Motor control enhancement · Spontaneous body sensations · Vibrations / buzzing · Abnormal heartbeat
Restlessness · Physical fatigue · Muscle tension · Excessive sweating · Heart rate perception changes · Tingling / electric sensations · Dehydration sensation · Tactile euphoria · Bodily lightness · Body high · Constipation · Headache · Nausea · Sexual arousal enhancement · Trembling · Bruxism · Motor control enhancement · Spontaneous body sensations · Vibrations / buzzing
Motivation enhancement · Analysis enhancement · Information processing enhancement · Motivation suppression · Aesthetic enhancement · Cognitive flexibility · Immersion enhancement · Thought organization · Language enhancement · Memory enhancement · Creativity enhancement · Thought deceleration
Aesthetic enhancement · Cognitive flexibility · Immersion enhancement · Thought organization · Language enhancement · Memory enhancement · Creativity enhancement · Thought deceleration
Irritability · Anhedonia · Emotional enhancement · Anxiety suppression
Social connection · Flow state
Timeline
Gradual awareness of increased alertness and mild appetite changes. Effects emerge subtly — a slight sharpening of attention without a distinct perceptual shift.
Building stimulation with focus sharpening and mood elevation beginning. Heart rate increases noticeably. Wakefulness intensifies and appetite suppression becomes evident.
Full stimulant effects — pronounced wakefulness, cognitive euphoria, focus enhancement, appetite suppression, and physical stimulation. Motivation and thought acceleration are at maximum intensity. Bruxism and sweating may be present at higher doses.
Gradual decline in stimulation with onset of fatigue. Irritability and restlessness may emerge as catecholamine levels fall. Focus and motivation begin to wane.
Residual wakefulness or insomnia, mild physical fatigue, and possible depressed mood. Appetite gradually returns. Cognitive fatigue and motivation suppression may persist for several hours.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 5.5 days
- Physical
- Moderate
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · cocaine
Toxicity
Acute toxicity
No lethal dose has been established in any species, and no human overdose reports or postmortem cases have been published.safety citation needed Amphetamine-type overdose produces dangerous body temperature elevation, rapid heart rate, high blood pressure, agitation, dilated pupils, and seizure risk.[16] Body temperature elevation is the single greatest predictor of death in stimulant overdose.
Treatment centers on benzodiazepines for agitation and seizure prevention, active cooling for temperature elevation, and avoiding beta-blockers, which risk dangerous vasoconstriction. Antipsychotics carry seizure and heart rhythm risks and are not preferred.[17]
Cardiovascular effects
3-FA's potent norepinephrine release drives rapid heart rate, elevated blood pressure, and increased cardiac workload. Heart rhythm disturbances are possible at high doses.[16]
Fluorinated amphetamines as a class have been linked to heart failure, brain hemorrhage, and death[6] — events documented primarily for 4-FA, including fatalities involving 4-FA combined with other substances.[18] No cardiovascular events have been specifically attributed to 3-FA in published literature.safety citation needed
Neurotoxicity
Methamphetamine damages dopamine-producing nerve terminals through oxidative stress. Whether 3-FA shares this liability is unknown — no neurotoxicity studies have been conducted. Given comparable dopamine-releasing potency, the risk cannot be ruled out.safety citation needed
Psychological risks
No published data on psychological adverse effects in humans exist. By mechanism and class:
- Stimulant psychosis: Extended high-dose use can produce paranoid delusions, hallucinations, and thought disorganization. Risk scales with dose, duration, and sleep deprivation.inferred
- Anxiety and paranoia: Elevated catecholamine levels produce acute anxiety and paranoia, particularly at high doses or during extended use.
- Compulsive redosing: The dopamine-selective profile, without serotonin's self-limiting effect, makes compulsive redosing a well-documented risk.
- Post-use crash: Catecholamine depletion produces depressed mood, anhedonia, fatigue, and irritability. Severity scales with dose and duration.
Tolerance & dependence
Tolerance develops as the brain reduces dopamine receptor density and increases transporter levels in response to repeated overstimulation — higher doses become necessary for the same effect. Cross-tolerance with other dopaminergic stimulants is expected.inferred
Dependence liability is confirmed by preclinical data. Rhesus monkeys self-administer 3-FA at rates comparable to other dopamine-selective amphetamine analogs.[1] The compound lacks the serotonergic brake that reduces reinforcing efficacy in MDMA-like compounds,[1] and its abuse potential has been assessed as comparable to methamphetamine.[6]
Physical withdrawal has not been characterized but is anticipated at moderate levels. Amphetamine withdrawal produces fatigue, excessive sleep, appetite enhancement, and depressed mood — it is not life-threatening.inferred
Drug interactions
Combining 3-FA with any monoamine oxidase inhibitor (MAOI) is potentially lethal. Monoamine oxidase inhibitors block the breakdown of dopamine and norepinephrine inside neurons; adding a releasing agent causes massive accumulation of these chemicals, producing dangerously high blood pressure and body temperature.[19] This applies to irreversible MAOIs (phenelzine, tranylcypromine), reversible MAO-A inhibitors (moclobemide), and selegiline at higher doses.
Tramadol inhibits serotonin reuptake and lowers the seizure threshold. Combined with a monoamine releaser — even one with low serotonergic potency — serotonin syndrome risk exists alongside seizure risk. This combination is classified as potentially lethal.safety citation needed
Other stimulants (cocaine, other amphetamines, sympathomimetics) add cardiovascular stress: heart rate, blood pressure, and heart rhythm risks increase multiplicatively. PCP compounds these effects with additional brain excitotoxicity, temperature elevation, and psychosis risk.safety citation needed
CNS depressants (alcohol, GHB/GBL) may mask the subjective signs of stimulant intoxication without reducing cardiovascular stress — creating a gap between how a person feels and what is actually happening in their body.
Caffeine adds mild cardiovascular stimulation at typical doses and may worsen rapid heart rate and anxiety in sensitive individuals.
Contraindications
No substance-specific contraindication data exist. The following are derived from 3-FA's mechanism as a potent catecholamine-releasing agent.inferred
- Heart conditions (absolute): Pre-existing cardiac disease — coronary artery disease, cardiomyopathy, irregular rhythms, structural defects — is an absolute contraindication. Rapid heart rate, elevated blood pressure, and increased oxygen demand can trigger acute cardiac events.
- High blood pressure (absolute): Catecholamine release produces acute blood pressure spikes that compound pre-existing hypertension, increasing stroke and aortic dissection risk.
- Concurrent MAOI use (absolute): Potentially lethal via dangerously elevated blood pressure and temperature, as detailed above.
- Seizure disorders (relative): Stimulant-driven sympathetic activation lowers the seizure threshold.
- Overactive thyroid (relative): Excess thyroid hormone amplifies catecholamine sensitivity; 3-FA compounds this effect.
- Pregnancy (absolute): Catecholamine-releasing agents constrict uterine blood vessels and cause fetal rapid heart rate. No reproductive toxicity data exist for 3-FA.inferred
- Psychotic disorders (relative): Dopaminergic stimulation can trigger or worsen psychotic episodes in individuals with schizophrenia spectrum disorders or a history of stimulant-induced psychosis.
Harm Reduction[edit]
Forms & Identification
The structured data module above displays reagent test results, physical forms, and common substitution risks for 3-FA. Because 3-FA is distributed exclusively through unregulated research chemical channels, batch composition and purity are unverified by default. Reagent testing confirms the presence of an amphetamine-class compound but cannot distinguish between positional isomers (2-FA, 3-FA, 4-FA). This matters because the isomers differ substantially in pharmacological profile and risk.
Where possible, confirm identity with an analytical testing service that provides quantitative results.
Guidelines
- Weigh doses with a milligram-precision analytical scale — never estimate by eye.
- Reagent test every batch before use. A Marquis test confirms an amphetamine-class compound but cannot distinguish positional isomers.
- Start with the lowest reported active dose and wait at least 90 minutes before considering redosing — oral onset is gradual and premature redosing is a common path to overdose.
- Set a firm redosing limit before the session begins. 3-FA's dopaminergic profile promotes compulsive redosing — decisions made while stimulated are unreliable.
- Stay hydrated but do not overdrink — stimulants suppress thirst cues, but forced water intake can cause electrolyte imbalance.
- Eat a balanced meal before use. Appetite suppression will persist throughout the experience and into the following day.
- Plan for the comedown: have sleep aids (melatonin, magnesium), nutritious food, and a low-demand schedule for the day after.
Set & Setting
3-FA's dopaminergic profile produces sustained, task-oriented stimulation without euphoric warmth. A structured environment with clear activities channels the stimulation productively; unstructured settings risk restless agitation. Avoid use during periods of sleep deprivation — stimulant psychosis risk scales directly with time without sleep.
Aftercare & integration. The comedown following 3-FA use typically brings fatigue, low mood, irritability, and difficulty concentrating. These effects reflect temporary catecholamine depletion and generally resolve within 24–72 hours.
Recovery priorities: Sleep is the most important recovery tool — use melatonin or magnesium if needed, avoid further stimulant use (including excess caffeine), and allow the body to rest. Eat nutrient-dense meals even if appetite remains suppressed. Gentle physical activity can help restore normal mood faster than sedentary recovery.
If depressed mood, anhedonia, or fatigue persist beyond one week, or if use patterns are escalating, seek professional support.
Recovery & Support
Stimulant use disorders develop gradually — the transition from occasional use to compulsive redosing often occurs before a pattern is recognized. Warning signs include using more frequently or at higher doses than intended, neglecting responsibilities during or after use, and continuing despite negative consequences.
Evidence-based treatments include cognitive behavioral therapy, contingency management, and motivational interviewing. No approved medication exists specifically for amphetamine-type stimulant dependence, but clinical support significantly improves outcomes. SAMHSA's National Helpline (1-800-662-4357) provides free, confidential treatment referrals. SMART Recovery and mutual aid groups offer peer-based support.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Uncomfortable stimulation (jitteriness, mild anxiety, fast heart rate) is distinct from a medical emergency. Seek immediate help for: chest pain or pressure, seizure activity, loss of consciousness, body temperature so high it can be felt through clothing, severe confusion or paranoid psychosis, or inability to stop repetitive movements.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present.
- 2. Move the person to a cool, quiet environment.
- 3. Remove excess clothing and apply cool water to the skin if overheating.
- 4. Do not restrain the person unless they are in immediate danger of harming themselves or others.
- 5. Place an unconscious person in the recovery position (on their side, airway clear).
- 6. Do not induce vomiting.
What to tell the dispatcher: Name the substance (3-FA / 3-fluoroamphetamine), approximate amount taken, time of ingestion, and current symptoms. Many jurisdictions have Good Samaritan laws that protect people who call for help during a drug emergency.
No specific reversal agent exists for amphetamine-type stimulant overdose. Hospital treatment focuses on sedation with benzodiazepines, active cooling, and cardiovascular monitoring.
Legal Status[edit]
3-FA occupies an ambiguous legal position in most jurisdictions — it is not listed under any United Nations convention schedule and has not been assessed by the WHO Expert Committee on Drug Dependence as of May 2026.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the amphetamine analogue clause; maximum penalties equivalent to amphetamine[5] |
| Germany | NpSG (Neue-psychoaktive-Stoffe-Gesetz) | Controlled since November 26, 2016. Production, import for market placement, and trade are punishable; possession is prohibited but not separately penalized under NpSG[5] |
| United States | Not specifically scheduled | No permanent or emergency DEA scheduling as of May 2026. May be prosecuted as a controlled substance analogue under the Federal Analogue Act based on structural and pharmacological similarity to amphetamine; enforcement is case-dependentsafety citation needed |
| Canada | Likely Schedule III (CDSA) | Amphetamine analogues are controlled under Schedule III of the Controlled Drugs and Substances Act; 3-FA would likely fall under this provision, though no specific scheduling decision has been publicly confirmedcitation needed |
| Australia | Status unconfirmed | Amphetamine is listed in the SUSMP; analogues may fall under this provision depending on TGA interpretationcitation needed |
| New Zealand | Schedule 3 controlled substance | Classified as an amphetamine analoguecitation needed |
Analogue act considerations
3-FA's structural relationship to amphetamine — a single fluorine atom at the meta ring position — and its pharmacological profile (potent dopamine/norepinephrine releaser with methamphetamine-comparable effects[6]) make it a strong candidate for prosecution under structural analog provisions. The United States Federal Analogue Act requires substantial similarity in both chemical structure and pharmacological effect to a Schedule I or II controlled substance — criteria 3-FA plausibly meets. Analogue act prosecutions require case-by-case determination and are not equivalent to explicit scheduling.
Legal status varies by jurisdiction and changes without notice. Nothing here constitutes legal advice.
references
- [1]
- [2]
- [3] ^abcNegus SS, Mello NK, Blough BE, Baumann MH, Rothman RB (2007) Monoamine releasers with varying selectivity for dopamine/norepinephrine versus serotonin release as candidate agonist medications for cocaine dependence — The Journal of Pharmacology and Experimental Therapeutics PMID:17071819
- [4] ^abBanks ML, Blough BE, Negus SS (2011) Effects of monoamine releasers with varying selectivity for releasing dopamine/norepinephrine versus serotonin on choice between cocaine and food in rhesus monkeys — Behavioural Pharmacology doi:10.1097/fbp.0b013e32834d63ac
- [5]
- [6]